[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-340390-105":3,"detail-sidebar-cat-0-en-105":73,"doc-detail-340390-en":123},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":66,"head_meta":68,"extra_data":70,"updated_unix":72},105,"en","prostaglandin-e2-ep2ep4-signaling-induces-immunosuppression-in-human-cancer-by-impairing-bioenergetics-and-ribosome-biogenesis-in-immune-cells","Prostaglandin E2-EP2/EP4 signaling induces immunosuppression in human cancer by impairing bioenergetics and ribosome biogenesis in immune cells","","Prostaglandin E2 (PGE2) is present in the tumor microenvironment, yet its mechanisms of immunosuppression in progressive human cancer remain unclear. Using comparative single-cell RNA sequencing of immune cells infiltrating human cancers and syngeneic mouse tumors, the study links EP2/EP4 receptor expression to reduced oxidative phosphorylation, glycolysis, MYC targets, and ribosome protein biogenesis. EP2/EP4 activation suppresses IL-2–STAT5 signaling, downregulating c-Myc and PGC-1α to impair immune cell migration, expansion, survival, and antitumor activity.",{"@graph":14,"@context":65},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/prostaglandin-e2-ep2ep4-signaling-induces-immunosuppression-in-human-cancer-by-impairing-bioenergetics-and-ribosome-biogenesis-in-immune-cells/340390/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/prostaglandin-e2-ep2ep4-signaling-induces-immunosuppression-in-human-cancer-by-impairing-bioenergetics-and-ribosome-biogenesis-in-immune-cells/340390.png","ImageObject",300,407,{"name":42,"@type":43},"Eden","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59],{"name":60,"@type":61,"acceptedAnswer":62},"What evidence supports a causal role for PGE2-EP2/EP4 in tumor immunosuppression?","Question",{"text":63,"@type":64},"Mouse LLC1 tumors treated with EP2 and EP4 antagonists reverse the PGE2-associated downregulation of bioenergetics and ribosome biogenesis in both lymphocytes and tumor-infiltrating myeloid cells.","Answer","https://schema.org",{"og:url":32,"og:type":67,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":69,"canonical":32},"index,follow",{"doc_id":71,"site_id":7},340390,1790144837,{"code":4,"msg":74,"data":75},"success",[76,80,84,88,93,98,103,107,112,115,119],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":77,"show_sort_weight":78,"slug":79},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":81,"show_sort_weight":82,"slug":83},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Exam",70,"exam",{"id":89,"doc_module":4,"doc_module_name":25,"category_name":90,"show_sort_weight":91,"slug":92},5,"Comic",60,"comic",{"id":94,"doc_module":4,"doc_module_name":25,"category_name":95,"show_sort_weight":96,"slug":97},6,"Technology",50,"technology",{"id":99,"doc_module":4,"doc_module_name":25,"category_name":100,"show_sort_weight":101,"slug":102},7,"Healthcare",40,"healthcare",{"id":104,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":105,"slug":106},8,30,"research-report",{"id":108,"doc_module":4,"doc_module_name":25,"category_name":109,"show_sort_weight":110,"slug":111},9,"Religion & Spirituality",20,"religion-spirituality",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":113,"show_sort_weight":110,"slug":114},"World Cup","world-cup",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":116,"slug":118},10,"Lifestyle","lifestyle",{"id":120,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":89,"slug":122},19,"General","general",{"code":4,"msg":74,"data":124},{"doc_id":71,"user_id":125,"nickname":42,"user_avatar":126,"doc_module":4,"category_id":104,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":127,"file_id":128,"file_url":129,"file_type":130,"file_size":131,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":120,"language":132,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":133,"faqs":134,"seo_title":135,"seo_description":12,"update_tm":136,"read_time":137,"preview_page_count":33,"preview_urls":138},1374391974468,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Article [https://doi.org/10.1038/s41467-024-53706-3](https://doi.org/10.1038/s41467-024-53706-3)  \nProstaglandin E2-EP2/EP4 signaling induces immunosuppression in human cancer by impairing bioenergetics and ribosome biogenesis in immune cells  \nReceived: 30 May 2024  \n\n| Accepted: 21 October 2024 |\n| --- |\n| |\n| Check for updates |\n\nSiwakorn Punyawatthananukool1, Ryuma Matsuura1, Thamrong Wongchang1,17, Nao Katsurada1, Tatsuaki Tsuruyama1,2, Masaki Tajima 3, Yutaka Enomoto4, Toshio Kitamura 4,5, Masahiro Kawashima 6, Masakazu Toi 6,  \nKoji Yamanoi 7, Junzo Hamanishi 7, Shigeo Hisamori8, Kazutaka Obama8, Varodom Charoensawan 9,10,11,12,13,14, Dean Thumkeo 1 &  \nShuh Narumiya 1,15,16   \nWhile prostaglandin E2 (PGE2) is produced in human tumor microenvironment (TME), its role therein remains poorly understood. Here, we examine this issue by comparative single-cell RNA sequencing of immune cells inﬁltrating human cancers and syngeneic tumors in female mice. PGE receptors EP4 and EP2 are expressed in lymphocytes and myeloid cells, and their expression is associated with the downregulation of oxidative phosphorylation (OXPHOS) and MYC targets, glycolysis and ribosomal proteins (RPs). Mechanistically, CD8+ T cells express EP4 and EP2 upon TCR activation, and PGE2 blocks IL-2-STAT5 signaling by downregulating Il2ra, which downregulates c-Myc and PGC-1 to decrease OXPHOS, glycolysis, and RPs, impairing migration, expansion, survival, and antitumor activity. Similarly, EP4 and EP2 are induced upon macrophage activation, and PGE2 downregulates c-Myc and OXPHOS in M1-like macrophages. These results suggest that PGE2-EP4/EP2 signaling impairs both adaptive and innate immunity in TME by hampering bioenergetics and ribosome biogenesis of tumor-inﬁltrating immune cells.  \nGiven the epidemiological ﬁnding that daily aspirin use lowers the risk of cancer-death1 and the association of high COX expression in tumor tissues with poor prognois2,3, the use of aspirin-like nonsteroidal antiinﬂammatory drugs (NSAIDs) as chemo-preventive and therapeutic agents for cancer has been repeatedly tested. However, the gastrointestinal toxicity associated with general NSAIDs and the cardiovascular toxicity of COX2 inhibitors have hampered their extensive use4,5. Such failure has led to the suggestion of manipulation of downstream PG signaling, particularly that of PGE2, the most abundant PG at tumor sites6,7, as an alternative measure. PGE2 acts on four subtypes of GPCR, EP1 to EP4, to exert its actions8. Among these PGE receptors, EP2 and  \nEP4 are expressed at elevated levels in tumor tissues such as colorectal cancer6,9,10, and antitumor potency of EP2 and EP4 antagonists have been shown repeatedly in various animal models11–15 and varied action mechanisms have been suggested11–21. Based on these ﬁndings, several EP4 antagonists and an EP2/4 dual antagonist are currently under investigation in clinical trials for different solid cancers22–24 (NCT04344795, NCT02540291, NCT03152370, NCT04432857, NCT03155061, NCT03661632, NCT03658772, NCT02538432), but these trials are without much insights into how PGE2-EP4/EP2 signaling functions inhuman cancer. Given epidemiological ﬁndings that aspirin use can improve the survival of patients with colorectal cancer after  \nA full list of afﬁliations appears at the end of the paper. e-mail: [narumiya.shuh.7a@kyoto-u.ac.jp](narumiya.shuh.7a@kyoto-u.ac.jp)  \ndiagnosis25,26, we hypothesized that PGE2 signaling not only functions in tumorigenesis but facilitates its progression. One possible PGE2 action is the induction of immunosuppression in tumor microenvironment (TME). While animal model studies have suggested many PGE2-mediated immunosuppression mechanisms in TME6,16–21, what PGE2 actually does to suppress immunity in progressive human cancer remains elusive.  \nIn this study, we investigate the gene expression signature associated with EP4 and EP2 expression in immune cells inﬁltrating human cancers using single-cell RNA se","cbCaikYvk3DCT6Lr","https://ap.wps.com/l/cbCaikYvk3DCT6Lr","pdf",7519972,"English","# Results\n## Immunological landscape of PGE2 signaling in human tumors","[{\"question\":\"What evidence supports a causal role for PGE2-EP2/EP4 in tumor immunosuppression?\",\"answer\":\"Mouse LLC1 tumors treated with EP2 and EP4 antagonists reverse the PGE2-associated downregulation of bioenergetics and ribosome biogenesis in both lymphocytes and tumor-infiltrating myeloid cells.\"}]","Prostaglandin E2-EP2/EP4 signaling induces immunosuppression in human cancer by impairing bioenergetics and ribosome biogenesis in immune cells | PDF",1790036221,48,[139,143,147,151],{"page_no":22,"url":140,"width":141,"height":142},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b537424e4f5449161aea6768f2f44c97.webp",983,1305,{"page_no":26,"url":144,"width":145,"height":146},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/53f16a140d4256bbd3d6540c9a5819a2.webp",982,1304,{"page_no":30,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/292da7ef47ba101238b99a3fe2674b1b.webp",981,1303,{"page_no":33,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/337abc6d1ef8a6a9d68f1fc95712f339.webp",980,1301]